Cutler Group LP Sesen Bio, Inc. Call Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 04, 2022	SELL	$0.38 - $0.89 $874 - $2,047	-2,300 Reduced 71.88%	900 $0
Q1 2022 Apr 14, 2022	SELL	$0.58 - $0.86 $30,507 - $45,236	-52,600 Reduced 94.27%	3,200 $0
Q4 2021 Jan 18, 2022	SELL	$0.73 - $1.28 $28,981 - $50,816	-39,700 Reduced 41.57%	55,800 $3,000
Q3 2021 Oct 26, 2021	BUY	$0.77 - $4.91 $15,939 - $101,637	20,700 Added 27.67%	95,500 $6,000
Q2 2021 Jul 19, 2021	BUY	$2.18 - $4.66 $114,450 - $244,650	52,500 Added 235.43%	74,800 $88,000
Q1 2021 Apr 26, 2021	BUY	$1.3 - $3.24 $28,860 - $71,928	22,200 Added 22200.0%	22,300 $25,000
Q4 2020 Jan 21, 2021	SELL	$1.01 - $1.77 $20,099 - $35,223	-19,900 Reduced 99.5%	100 $0
Q3 2020 Oct 27, 2020	BUY	$0.67 - $1.4 $13,400 - $28,000	20,000 New	20,000 $11,000
Q1 2019 May 10, 2019	SELL	$0.69 - $1.47 $138 - $294	-200 Closed	0 $0
Q4 2018 Feb 05, 2019	SELL	$0.96 - $2.04 $864 - $1,836	-900 Reduced 81.82%	200 $0
Q2 2018 Aug 10, 2018	BUY	$1.04 - $3.29 $1,144 - $3,619	1,100 New	1,100 $0

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.